<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544296</url>
  </required_header>
  <id_info>
    <org_study_id>6188-004</org_study_id>
    <nct_id>NCT01544296</nct_id>
  </id_info>
  <brief_title>A Comparative Study of KHK6188</brief_title>
  <official_title>Phase II Study of KHK6188 (A Placebo-controlled, Double Blind, Crossover Study of KHK6188 in Postherpetic Neuralgia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, double blind, crossover study to evaluate the efficacy and
      safety of KHK6188 in postherpetic neuralgia when administered orally for 2 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pain intensity score</measure>
    <time_frame>baseline and 2weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of allodynia severity</measure>
    <time_frame>baseline and 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of global impression</measure>
    <time_frame>baseline and 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>KHK6188, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KHK6188, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK6188</intervention_name>
    <arm_group_label>KHK6188, high dose</arm_group_label>
    <arm_group_label>KHK6188, low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pain for ≥ 3 months and ≤ 1 year following onset of a herpes zoster rash

          -  Patients with a mean pain intensity score (11-point numerical rating scale) of ≥ 4

          -  Patients whose rash has been healed

          -  Patients who are able to fill their patient diary

          -  Patients who provided written voluntary informed consent to participate in the study

        Exclusion Criteria:

          -  Patients who have other pain or disease which may impair the self assessment of pain

          -  Patients who have dementia, depression or schizophrenia which may affect the self
             assessment of pain

          -  History or presence of severe cardiovascular disease, hepatic dysfunction, renal
             failure, respiratory disease, blood disease or CNS disorder

          -  History or presence of a drug allergy

          -  Patients who have a history of a diagnosis of cancer or a treatment of cancer within 5
             years prior to the study entry

          -  Patients received an investigational medication within 4 months (6 months for biologic
             medication such as antibody) prior to the informed consent

          -  Women of child bearing potential who do not agree to avoid pregnancy from the time of
             providing the consent until 3 months after the end of dosing, or men of reproductive
             potential who do not agree to avoid pregnancy from the time of the first dose until 3
             months after the end of dosing

          -  Patients who are pregnant, lactating, or possibly pregnant

          -  Patients judged to be inappropriate to enter the study by a investigator or a
             subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Japan</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

